ISRCTN81218776 https://doi.org/10.1186/ISRCTN81218776

A study of adjuvant chemotherapy for malignant glioma

Submission date 28/02/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 28/02/2001	**Overall study status** Completed	
Last Edited 12/04/2012	**Condition category** Cancer	

Plain English summary of protocol
http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=101

Contact information

Type(s)
Scientific

Contact name
Dr Hannah Brooks

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
BR05

Study information

Scientific Title

Study objectives
To assess whether the addition of chemotherapy to a standard radiotherapy regime influences the survival of adult patients with malignant glioma (astrocytomas grades 3 & 4) and to assess the ability of in vitro chemosensitivity testing to identify patients with a better prognosis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Cancer

Interventions
1. One group receives chemotherapy added to a standard radiotherapy regimen
2. The other group receives none

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Chemotherapy

Primary outcome measure
Survival time

Secondary outcome measures

Not provided at time of registration

Overall study start date
01/09/1988

Completion date
30/06/1996

Eligibility

Key inclusion criteria
1. Age 18-69
2. No previous treatment except surgery, corticosteroids, anticonvulsants or diuretics
3. Entry within 6 weeks of surgery
4. Other malignancies
5. Fitness for treatment

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Upper age limit
69 Years

Sex
Both

Target number of participants
600

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/09/1988

Date of final enrolment
30/06/1996

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/01/2001		Yes	No